The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Neurogranin as a predictor of memory and executive function decline in MCI patients
Open accessAbstract
Objective To determine whether high CSF levels of neurogranin (Ng) predict longitudinal decline in memory and executive function during early-stage Alzheimer disease (AD). Methods Baseline levels of CSF Ng were studied in relation to cross-sectional and longitudinal cognitive performance over 8 years. Data were obtained from the Alzheimer9s Disease Neuroimaging Initiative database, and participants with normal cognition (n = 111) and mild cognitive impairment (MCI) (n = 193) were included. Results High levels of CSF Ng were associated with poor baseline memory scores (β = −0.21, p < 0.0001). CSF Ng predicted both memory and executive function decline over time (β = −0.0313, p = 0.0068 and β = −0.0346, p = 0.0169, respectively) independently of age, sex, education, and APOE ε4 status. When the rate of decline by tertiles was examined, CSF Ng was a level-dependent predictor of memory function, whereby the group with highest levels of Ng showed the fastest rates of decline in both memory and executive function. When examined separately, elevated Ng was associated with cognitive decline in participants with MCI but not in those with normal cognition. The levels of CSF Ng were not associated with cognitive measures when tau and amyloid 42 (Aβ42) were controlled for in these analyses. Conclusions High CSF Ng associates with poor memory scores in participants with MCI cross-sectionally and with poor memory and executive function longitudinally. The association of Ng with cognitive measures disappears when tau and Aβ42 are included in the statistical models. Our findings suggest that CSF Ng may serve as a biomarker of cognition. Synaptic dysfunction contributes to cognitive impairment in early-stage AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CSF Ng level can be used to determine and assess the effect of treatment as well as during progression of AD.
“CSF Ng level can be used to determine and assess the effect of treatment as well as during the progression of AD [96].”
From Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease (2020) · cites this paper as [96]
Neurogranin has significant association with memory and execution in MCI subjects, with increased level in CSF of AD and MCI patients compared to controls with normal cognitive ability.
“It has significant association with memory and execution in MCI subjects with an increased level in the CSF of AD and MCI patients compared to control with normal cognitive ability.”
From Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease (2020) · cites this paper as [96]
Neurogranin (Ng) has been identified as a biomarker for MCI.
“Recently a postsynaptic protein named neurogranin (Ng) has been identified as a biomarker for MCI.”
From Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease (2020) · cites this paper as [96]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863
Self-citationAmyloid-β–induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks
Palop, J. J., & Mucke, L. (2010) · Nature Neuroscience · doi:10.1038/nn.2583 · Cited by 1,651
The Intersection of Amyloid Beta and Tau at Synapses in Alzheimer’s Disease
Spires-Jones, T. L., & Hyman, B. T. (2014) · Neuron · doi:10.1016/j.neuron.2014.05.004 · Cited by 1,201
Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior
Selkoe, D. J. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.02.016 · Cited by 1,038
Initiative, A. D. N., Crane, P. K., Carle, A. C., Gibbons, L. E., Insel, P. S., Mackin, R. S., Gross, A. L., Jones, R. N., Mukherjee, S., Curtis, S. M., et al. (2012) · Brain Imaging and Behavior · doi:10.1007/s11682-012-9186-z · Cited by 634
Oligomeric Aβ-induced synaptic dysfunction in Alzheimer’s disease
Tu, S., Okamoto, S., Lipton, S. A., & Xu, H. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-48 · Cited by 613
Spine growth precedes synapse formation in the adult neocortex in vivo
Knott, G. W., Holtmaat, A., Wilbrecht, L., Welker, E., & Svoboda, K. (2006) · Nature Neuroscience · doi:10.1038/nn1747 · Cited by 563
Initiative, A. D. N., Gibbons, L. E., Carle, A. C., Mackin, R. S., Harvey, D. J., Mukherjee, S., Insel, P. S., Curtis, S. M., Mungas, D., & Crane, P. K. (2012) · Brain Imaging and Behavior · doi:10.1007/s11682-012-9176-1 · Cited by 511
The Clinical Problem of Symptomatic Alzheimer Disease and Mild Cognitive ImpairmentPreprint
Tarawneh, R. M., & Holtzman, D. M. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006148 · Cited by 493
Grober, E. H., Hall, C. B., Lipton, R. B., Zonderman, A. B., Resnick, S. M., & Kawas, C. H. (2008) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617708080302 · Cited by 458
Kvartsberg, H., Duits, F. H., Ingelsson, M., Andreasen, N., Öhrfelt, A., Andersson, K., Brinkmalm, G., Lannfelt, L., Minthon, L., Hansson, O., et al. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.10.009 · Cited by 349
Self-citationCerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer’s disease
Portelius, E., Zetterberg, H., Skillbäck, T., Törnqvist, U., Andreasson, U., Trojanowski, J. Q., Weiner, M. W., Shaw, L. M., & Mattsson, N. (2015) · Brain · doi:10.1093/brain/awv267 · Cited by 279
Self-citationKnopman, D. S., Boeve, B. F., & Petersen, R. C. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.10.1290 · Cited by 257
Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease
Kester, M. I., Teunissen, C. E., Crimmins, D. L., Herries, E. M., Ladenson, J. H., Scheltens, P., van der Flier, W. M., Morris, J. C., Holtzman, D. M., & Fagan, A. M. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.1867 · Cited by 246
Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease
Tarawneh, R. M., D’Angelo, G., Crimmins, D. L., Herries, E. M., Griest, T. A., Fagan, A. M., Zipfel, G. J., Ladenson, J. H., Morris, J. C., & Holtzman, D. M. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.0086 · Cited by 228
Ralph, M. A. L., Patterson, K. E., Graham, N. L., Dawson, K., & Hodges, J. R. (2003) · Brain · doi:10.1093/brain/awg236 · Cited by 227
Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease
Thorsell, A., Bjerke, M., Gobom, J., Brunhage, E., Vanmechelen, E., Andreasen, N., Hansson, O., Minthon, L., Zetterberg, H., & Blennow, K. (2010) · Brain Research · doi:10.1016/j.brainres.2010.09.073 · Cited by 204
Self-citationAmyloid-Dependent and Amyloid-Independent Stages of Alzheimer Disease
Hyman, B. T. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.70 · Cited by 194
Miyakawa, T., Yared, E., Pak, J. H., Huang, F. L., Huang, K., & Crawley, J. N. (2001) · Hippocampus · doi:10.1002/hipo.1092 · Cited by 180
Neurochemical Dissection of Synaptic Pathology in Alzheimer's Disease
Davidsson, P., & Blennow, K. (1998) · International Psychogeriatrics · doi:10.1017/s1041610298005110 · Cited by 180
Self-citationVos, A. D., Jacobs, D., Struyfs, H., Fransén, E., Andersson, K., Portelius, E., Andréasson, U., Surgeloose, D. D., Hernalsteen, D., Sleegers, K., et al. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.05.012 · Cited by 158
Self-citationNeurogranin enhances synaptic strength through its interaction with calmodulin
Zhong, L., Cherry, T., Bies, C. E., Florence, M. A., & Gerges, N. Z. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.236 · Cited by 158
Dickerson, B. C., Wolk, D. A., & Initiative, T. A. D. N. (2010) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.199505 · Cited by 139
Volumetric atrophy of the amygdala in Alzheimer's disease
Scott, S. A., DeKosky, S. T., & Scheff, S. W. (1991) · Neurology · doi:10.1212/wnl.41.3.351 · Cited by 126
Pereira, J. B., Westman, E., & Hansson, O. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.06.002 · Cited by 120
Blennow, K., & Zetterberg, H. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00345 · Cited by 79
Self-citationNeurogranin controls the spatiotemporal pattern of postsynaptic Ca2+/CaM signaling.
Kubota, Y., Putkey, J., & Waxham, M. (2007) · Biophysical Journal · doi:10.1529/biophysj.107.106849 · Cited by 52
Isolated Executive Impairment and Associated Frontal Neuropathology
Johnson, J. K., Vogt, B., Kim, R., Cotman, C., & Head, E. (2004) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000078183 · Cited by 44
APOE ε4 carriers may undergo synaptic damage conferring risk of Alzheimer's disease
Sun, X., Dong, C., Levin, B. E., Crocco, E., Loewenstein, D., Zetterberg, H., Blennow, K., Wright, C. B., & Initiative, A. D. N. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.05.003 · Cited by 44
Self-citationThe executive prominent/memory prominent spectrum in Alzheimer's disease is highly heritable
Mez, J. B., Mukherjee, S., Thornton, T. A., Fardo, D. W., Trittschuh, E. H., Sutti, S., Sherva, R., Kauwe, J. S. K., Naj, A. C., Beecham, G. W., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.02.015 · Cited by 10
Flagged first, then by citations
Cited by
Sorted by citations
Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease
Khan, S., Barve, K. H., & Kumar, M. S. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200528142429 · Cited by 820
“CSF Ng level can be used to determine and assess the effect of treatment as well as during the progression of AD [96].”
MethodThawkar, B. S., & Kaur, G. (2018) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2018.11.010 · Cited by 254
Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's disease
Libiger, O., Shaw, L. M., Watson, M. H., Nairn, A. C., Umaña, K. L., Biarnes, M. C., Canet‐Avilés, R. M., Jack, C. R., Breton, Y., Cortes, L., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12353 · Cited by 108
Liu, W., Lin, H., He, X., Chen, L., Dai, Y., Jia, W., Xue, X., Tao, J., & Chen, L. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0801-2 · Cited by 117
Kern, S., Syrjanen, J. A., Blennow, K., Zetterberg, H., Skoog, I. G., Wærn, M., Hagen, C. E., van Harten, A. C., Knopman, D. S., Jack, C. R., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.3459 · Cited by 100
Self-citationDissection of synaptic pathways through the CSF biomarkers for predicting Alzheimer disease
Tible, M., Sandelius, Å., Höglund, K., Brinkmalm, A., Cognat, E., Dumurgier, J., Zetterberg, H., Hugon, J., Paquet, C., & Blennow, K. (2020) · Neurology · doi:10.1212/wnl.0000000000010131 · Cited by 83
Self-citationCompta, Y., & Révész, T. (2020) · Journal of Parkinson s Disease · doi:10.3233/jpd-202323 · Cited by 61
Mavroudis, I. A., Petridis, F., Chatzikonstantinou, S., & Kazis, D. A. (2019) · Aging Clinical and Experimental Research · doi:10.1007/s40520-019-01326-z · Cited by 53
Öhrfelt, A., Benedet, A. L., Ashton, N. J., Kvartsberg, H., Vandijck, M. L. J., Weiner, M. W., Trojanowski, J. Q., Shaw, L. M. J., Zetterberg, H., Blennow, K., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000201417 · Cited by 44
Self-citationNeurogranin as biomarker in CSF is non-specific to Alzheimer's disease dementia
Willemse, E. A. J., Sieben, A., Somers, C., Vermeiren, Y., De Roeck, N., Timmers, M., Van Broeckhoven, C., De Vil, B., Cras, P., De Deyn, P. P., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.08.002 · Cited by 34
Biomarkers of synaptic degeneration in Alzheimer’s disease
Cheng, Q., Fan, Y., Zhang, P., Liu, H., Han, J., Yu, Q., Wang, X., Wu, S., & Lu, Z. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102642 · Cited by 38
Dulewicz, M., Kulczyńska‐Przybik, A., & Mroczko, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218335 · Cited by 35
Gessi, S., Poloni, T. E., Negro, G., Varani, K., Pasquini, S., Vincenzi, F., Borea, P. A., & Merighi, S. (2021) · Cells · doi:10.3390/cells10092344 · Cited by 36
The role of synaptic biomarkers in the spectrum of neurodegenerative diseases
Mazzucchi, S., Palermo, G., Campese, N., Galgani, A., Vecchia, A. D., Vergallo, A., Siciliano, G., Ceravolo, R., Hampel, H. J., & Baldacci, F. (2020) · Expert Review of Proteomics · doi:10.1080/14789450.2020.1831388 · Cited by 33
Differential effects of neurodegeneration biomarkers on subclinical cognitive decline
Merluzzi, A. P., Vogt, N. M., Norton, D., Jonaitis, E. M., Clark, L. R., Carlsson, C. M., Johnson, S. C., Asthana, S., Blennow, K., Zetterberg, H., et al. (2019) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.02.004 · Cited by 28
Self-citationEarly-stage Alzheimer’s disease profiling in blood achieved by multiplexing aptamer-SERS biosensors
Muhammad, M., Liu, C., Ge, Y., Shao, C., Xiong, L., Xia, H., Iqbal, J., Zhan, J., Qu, F., & Huang, Q. (2024) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2024.116907 · Cited by 28
Garrido‐García, A., de Andrés, R., Jiménez‐Pompa, A., Soriano, P., Sanz-Fuentes, D., Martínez‐Blanco, E., & Díez-Guerra, F. J. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-1593-3 · Cited by 28
Xue, M., Initiative, A. D. N., Sun, F.-R., Ou, Y., Shen, X., Li, H., Huang, Y., Dong, Q., Tan, L., & Yu, J. (2020) · Aging · doi:10.18632/aging.103211 · Cited by 25
Yoong, S. Q., Lu, J., Xing, H., Gyanwali, B., Tan, Y., & Wu, X. V. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101491 · Cited by 23
Lin, H., Zhang, J., Dai, Y., Liu, H., He, X., Chen, L., Tao, J., Li, C., & Liu, W. (2022) · Journal of sport and health science/Journal of Sport and Health Science · doi:10.1016/j.jshs.2022.01.008 · Cited by 23
Dakterzada, F., Benitez, I. D., Targa, A., Lladó, A., Torres, G., Romero, L., de Gonzalo‐Calvo, D., Moncusí‐Moix, A., Tort‐Merino, A., Huerto, R. P., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.705989 · Cited by 22
Giampietri, L., Belli, E., Beatino, M. F., Giannoni, S., Palermo, G., Campese, N., Tognoni, G., Siciliano, G., Ceravolo, R., Luca, C. D., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12040796 · Cited by 22
Nakajima, R., Hattori, S., Funasaka, T., Huang, F. L., & Miyakawa, T. (2020) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12150 · Cited by 20
Öhrfelt, A., Dumurgier, J., Zetterberg, H., Vrillon, A., Ashton, N. J., Kvartsberg, H., Bouaziz-Amar, É., Hugon, J., Paquet, C., & Blennow, K. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00748-6 · Cited by 19
Self-citationBloniecki, V., Zetterberg, H., Aarsland, D., Vannini, P., Kvartsberg, H., Winblad, B. G., Blennow, K., & Freund‐Levi, Y. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00718-y · Cited by 21
Self-citationAdded value of cerebrospinal fluid multimarker analysis in diagnosis and progression of dementia
Álvarez, I., Díez-Fairén, M., Aguilar, M., González, J. M., Ysamat, M., Tartari, J. P., Cárcel, M., Alonso, Á., Brix, B., Arendt, P., et al. (2020) · European Journal of Neurology · doi:10.1111/ene.14658 · Cited by 17
He, M., Sun, L., Cao, W., Yin, C., Sun, W., Liu, P., Tan, L., Xu, Z., & Zhao, W. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-036990 · Cited by 14
Sun, X., Wang, Q., Blennow, K., Zetterberg, H., McCarthy, M., Loewenstein, D., Vontell, R., Yue, Z., & Zhang, B. (2021) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12162 · Cited by 13
Self-citationTripartite Relationship Among Synaptic, Amyloid, and Tau Proteins
Casaletto, K. B., Zetterberg, H., Blennow, K., Brinkmalm, A., Honer, W. G., Schneider, J. A., Bennett, D. A., Djukic, N. A., You, M. Y., Weiner‐Light, S., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000012145 · Cited by 14
Self-citationSaunders, T. S., Gadd, D. A., Spires‐Jones, T. L., King, D., Ritchie, C. W., & Terrera, G. M. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15656 · Cited by 12
Smailović, U., Ferreira, D., Ausén, B., Ashton, N. J., Koenig, T. W., Zetterberg, H., Blennow, K., & Jelić, V. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.755454 · Cited by 10
Self-citationJurasova, V., Andel, R., Katonová, A., Veverová, K., Zuntychová, T., Horáková, H., Vyhnálek, M., Kolářová, T., Maťoška, V., Blennow, K., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01566-w · Cited by 10
Self-citationSulcal morphology as cognitive decline predictor in older adults with memory complaints
Mortamais, M., Gutierrez, L., Balem, M., Bars, E. L., de Champfleur, N. M., Bouyahia, A., Marie Chupin, A., Perus, L., Fischer, C., Vellas, B. J., et al. (2022) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2022.02.003 · Cited by 9
Fluid Biomarkers in Dementia Diagnosis
Quinn, J. F., & Gray, N. E. (2024) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001497 · Cited by 8
Vontell, R., Gober, R., Dallmeier, J., Brzostowicki, D. J., Barreda, A., Blennow, K., Zetterberg, H., Kvartsberg, H., Gultekin, S. H., Vaccari, J. P. D. R., et al. (2024) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12444 · Cited by 7
Self-citationHao, Y., Liu, X., & Zhu, R. (2021) · Current Alzheimer Research · doi:10.2174/1567205018666211208142702 · Cited by 9
Vaccari, J. P. D. R., Davis, D. A., Sawaya, A. P., Garamszegi, S. P., Sun, X., Barreda, A., Bramlett, H. M., Gultekin, S. H., Dietrich, W. D., Keane, R. W., et al. (2026) · Brain Pathology · doi:10.1111/bpa.70086 · Cited by 6
Self-citationPark, J., Lee, S. H., Shin, D., Kim, Y., Kim, Y. S., Seong, M. Y., Lee, J. J., Seo, H. G., Cho, W., Ro, Y. S., et al. (2023) · Journal of Proteome Research · doi:10.1021/acs.jproteome.3c00544 · Cited by 6
Potential Application of MicroRNAs and Some Other Molecular Biomarkers in Alzheimer’s Disease
Paprzycka, O., Wieczorek, J., Nowak, I., Madej, M., & Strzałka‐Mrozik, B. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46060304 · Cited by 7
Association of Neurogranin with Delirium Among Critically Ill Patients
Wanderlind, M. L., Gonçalves, R. C., Tomasi, C. D., Dal‐Pizzol, F., & Ritter, C. (2020) · Biomarkers in Medicine · doi:10.2217/bmm-2020-0328 · Cited by 5
Synaptic protein CSF levels relate to memory scores in individuals without dementia
Wesenhagen, K. E. J., de Leeuw, D. M., Tomassen, J., Gobom, J., Bos, I., Vos, S. J. B., Martínez‐Lage, P., Tainta, M., Popp, J., Peyratout, G., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01703-z · Cited by 4
Self-citationLaudański, K., Liu, D., Okeke, T., Restrepo, M., & Szeto, W. Y. (2022) · Biomedicines · doi:10.3390/biomedicines10102364 · Cited by 4
Fluid Biomarkers in Clinical Trials for Alzheimer’s Disease: Current and Future Application
Yang, J., Jia, L., Li, Y., Qiu, Q., Quan, M., & Jia, J. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201068 · Cited by 4
Yu, X., Guo, J., Song, Y., Wei, B., Shi, Y., Zhao, Y., Zhao, Z., Gao, Q., Wang, B., & Sun, M. (2024) · The FASEB Journal · doi:10.1096/fj.202400389r · Cited by 3
Wang, X., Freiesleben, S. D., Schneider, L., Preis, L., Priller, J., Spruth, E. J., Altenstein, S., Schneider, A., Fließbach, K., Wiltfang, J., et al. (2024) · Neurology · doi:10.1212/wnl.0000000000209806 · Cited by 3
CSF VEGF Was Positively Associated with Neurogranin Independent of β-Amyloid Pathology
Huang, Y., Wang, J., Zhu, B., & Fu, P. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s252008 · Cited by 4
The Potential Role of Neurogranin in Alzheimer’s Disease
Zhou, X., Jing, X.-J., & Zhang, H. (2025) · Journal of Integrative Neuroscience · doi:10.31083/jin25368 · Cited by 4
Elevation of CSF Sortilin Following Subarachnoid Hemorrhage in Patients and Experimental Model Rats
Wang, Y., Wang, J., Zuo, Y., Jiang, J., Tu, T., Yan, X., & Liu, F. (2021) · Neuroscience · doi:10.1016/j.neuroscience.2021.07.004 · Cited by 3
Svirsky, S. E., Henchir, J. J., Parry, M., Holets, E., Zhang, T., Gittes, G. K., Carlson, S. W., & Dixon, C. E. (2024) · Scientific Reports · doi:10.1038/s41598-024-77682-2 · Cited by 2
Aravena, J. M., Castro, H., Poblete, R., Aravena, M. I., Torres, W., Vivar, P., Lara, E., Budinich, M., Fuentes, P. A., Cecilia Albala, B., et al. (2025) · Journal of the American Geriatrics Society · doi:10.1111/jgs.70251 · Cited by 3
Evaluation of neurogranin levels in a rat model of diffuse axonal injury
Başkurt, O., Aydın, S., Avcı, İ., Nayır, P. Ö., & Aydin, M. V. (2024) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2024-2543 · Cited by 2
The Diagnostic Value of Cerebrospinal Fluid Neurogranin in Neurodegenerative Diseases
Krawczuk, D., Mroczko, P., Winkel, I., & Mroczko, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413578 · Cited by 2
Pohlan, J., Leidel, B. A., & Lindner, T. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816346-7.00015-4 · Cited by 2
The fluid biomarkers of Alzheimer’s disease
Peng, Q., & Zhang, Z. (2021) · Brain Science Advances · doi:10.26599/bsa.2021.9050001 · Cited by 1
Sezgin, Z., ÖZAÇMAK, H. S., & TURAN, İ. (2025) · Neuroscience Letters · doi:10.1016/j.neulet.2025.138382 · Cited by 1
Shifting Paradigm in Early Detection and Prediction of Alzheimer's Disease
Bashir, T., Akhouri, D., & Hamza, H. (2024) · Advances in medical technologies and clinical practice book series · doi:10.4018/979-8-3693-1090-8.ch013 · Cited by 1
Dakterzada, F., Benitez, I. D., Targa, A., Lladó, A., Torres, G., Romero, L., de Gonzalo‐Calvo, D., Moncusí‐Moix, A., Tort‐Merino, A., Huerto, R. P., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-118289/v1 · Cited by 1
Żak, B., & Zbieg, A. (2014) · arXiv (Cornell University) · doi:10.48550/arxiv.1411.7727
Dakterzada, F., Benitez, I. D., Targa, A., Lladó, A., Torres, G., Romero, L., de Gonzalo‐Calvo, D., Moncusí‐Moix, A., Tort‐Merino, A., Huerto, R. P., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-125973/v1
Wang, S., Initiative, A. D. N., Liu, S., Ke, S., Zhou, W., & Pan, T. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230437 · Cited by 1
Neuromarkers predicting neurogranin in preclinical AlzheimerÓ?s using multilayer perceptron
Guevara-Tirado, A. (2025) · Archivos de Neurociencias (English ed ) · doi:10.24875/ance.m24000038
Wang, H., Ding, M., Shen, Y., Wei, H., Huang, Z., Teng, J., Song, J., Lu, Q., Huang, T., Liu, H., et al. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877251413723
Metadata
- Authors
- Headley, A., De Leon-Benedetti, A., Dong, C., Levin, B., Loewenstein, D., Camargo, C., Rundek, T., Zetterberg, H., Blennow, K., Wright, C. B., & Sun, X.
- Affiliations
- University of Miami (US)
- From the Department of Neuroscience (A.H.), University of California San Diego, La Jolla; Department of Neurology (A.D.L.-B., C.D., B.L., C.C., T.R., X.S.), Evelyn F. McKnight Brain Institute (B.L., C.C., T.R., X.S.), and Psychiatry and Behavioral Sciences (D.L.), University of Miami Miller School of Medicine, FL; Department of Psychiatry and Neurochemistry (H.Z., K.B.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University Gothenburg, Molndal, Sweden; Department of...
- ORCID
- Venue
- Neurology
- Published
- 2018-03-06
- Volume
- 90
- Issue
- 10
- Pages
- e887-e895
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- PMC
- PMC5863492
- OpenAlex
- W2788051073
- Cited by
- 62
- References
- 32
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 12 · 2023: 2 · 2022: 7 · 2021: 11 · 2020: 17 · 2019: 3 · 2018: 2
- FWCI
- 6.45
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Neurology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- National Institutes of Health (5u01ag024904-10)
- National Institute on Aging (U01-AG-024904)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- neurogranin, cerebrospinal fluid biomarkers, mild cognitive impairment, Alzheimer's disease, memory decline, executive function decline, cognitive decline prediction, tau protein, amyloid-beta 42, synaptic dysfunction, APOE ε4
- MeSH terms
- Aged, Aged, 80 and over, Apolipoproteins E, Cross-Sectional Studies, Female, Humans, Longitudinal Studies, Magnetic Resonance Imaging, Male, Memory Disorders, Middle Aged, Neuropsychological Tests, Peptide Fragments, Chi-Square Distribution, Amyloid beta-Peptides, tau Proteins, Neurogranin, Executive Function, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
